Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response

BACKGROUND: Approximately 15%–20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. Although improvements in treatment have been achieved after the introduction of trastuzumab and lapatinib,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer (Dove Med Press)
Main Authors: Jernström, Sandra, Hongisto, Vesa, Leivonen, Suvi-Katri, Due, Eldri Undlien, Tadele, Dagim Shiferaw, Edgren, Henrik, Kallioniemi, Olli, Perälä, Merja, Mælandsmo, Gunhild Mari, Sahlberg, Kristine Kleivi
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2017
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5367762/
https://ncbi.nlm.nih.gov/pubmed/28356768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S115600
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares